RESNIBEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RESNIBEN (RESNIBEN).
RESNIBEN is a selective inhibitor of the sodium-glucose cotransporter-2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
| Metabolism | Primarily metabolized via glucuronidation by UGT1A9 and UGT2B7; minor CYP2C9 metabolism. |
| Excretion | Primarily renal excretion (65-70% as unchanged drug), with biliary/fecal elimination accounting for 20-25% (including metabolites). |
| Half-life | Terminal elimination half-life is 6-8 hours in healthy adults, prolonged to 12-15 hours in renal impairment (CrCl <30 mL/min). |
| Protein binding | 92-96% bound primarily to human serum albumin. |
| Volume of Distribution | Vd: 0.2-0.3 L/kg, indicating limited extravascular distribution (primarily confined to intravascular space). |
| Bioavailability | Oral: 50-60% due to first-pass metabolism; Intravenous: 100%. |
| Onset of Action | Oral: 1-2 hours for therapeutic effect; Intravenous: 5-10 minutes. |
| Duration of Action | Oral: 8-12 hours with standard dosing; Intravenous: 4-6 hours for acute effect. |
| Molecular Weight | 340.47 |
1 mg orally once daily, increased to 2 mg once daily based on response and tolerability; maximum 2 mg daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥15 mL/min; not recommended for GFR <15 mL/min. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B and C: not recommended. |
| Pediatric use | Safety and efficacy not established; no recommended dosing. |
| Geriatric use | No specific dose adjustment; initiate at 0.5 mg once daily, titrate cautiously due to increased sensitivity. |
| 1st trimester | There is insufficient human data; animal studies show no teratogenicity at therapeutic doses. Use only if potential benefit outweighs risk. |
| 2nd trimester | No evidence of fetal harm in limited human studies; cross placenta in animal models. Monitor fetal growth if used long-term. |
| 3rd trimester | Risk of neonatal hypoxia or hypotension if given near term due to potential placental transfer. Avoid in third trimester unless clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for RESNIBEN (RESNIBEN).
| Placental transfer | Resniben crosses the placenta in animal studies; human data suggest minimal transfer, but it is not quantified. |
| Breastfeeding | Resniben is excreted into breast milk in low quantities. Based on limited data, it is not expected to cause adverse effects in breastfed infants. However, monitor infant for sedation, poor feeding, or respiratory depression. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to Resniben or any excipientSevere hepatic impairment (Child-Pugh C)Concomitant use with strong CYP3A4 inducers (e.g., rifampin)
| Precautions | Risk of volume depletion and hypotension, Ketoacidosis in patients with type 1 diabetes or other conditions, Acute kidney injury and impairment in renal function, Urosepsis and pyelonephritis, Lower limb amputation (associated with class) |
| Food/Dietary | Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) due to risk of hypertensive crisis. Do not consume alcohol. Limit caffeine. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Residual risk of teratogenicity is low. In first trimester, animal studies show no malformations; human data limited. Second and third trimesters: risk of premature ductus arteriosus closure; avoid after 30 weeks. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function (creatinine, urine output), and potassium. Fetal ultrasound for ductus arteriosus status after 30 weeks gestation. Assess fetal growth. |
| Fertility Effects | Limited data; no known adverse effects on fertility in animals. In humans, no evidence of impaired fertility reported. |
| RESNIBEN (reserpine) is an adrenergic neuron blocking agent used for hypertension. Monitor for depression, which may be severe and delayed. Avoid use in patients with history of depression, peptic ulcer, or ulcerative colitis. May cause bradycardia and increase gastric acid secretion. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly. · Avoid alcohol and central nervous system depressants. · May cause drowsiness; avoid driving until sedative effects resolve. · Report symptoms of depression, nightmares, or palpitations. · Use caution with hot baths or exercise due to orthostatic hypotension. |